Skip to main content

Gilteritinib

Gilteritinib for the Treatment of ALK NSCLC

  • RegistryNCT06225427
  • PhasePhase 1
  • StatusRecruiting
  • ConditionLung Non-Small Cell Carcinoma
  • SponsorUniversity of Michigan Rogel Cancer Center
How Gilteritinib worksNCT062254271 min

What the film says

Read the transcript

This trial is for stage 4 ALK positive non small cell lung cancer that has progressed on other treatments, in adults.

The idea: reuse an approved drug. Gilteritinib is already FDA approved for a specific type of leukemia. The record says studies using ALK positive lung cancer cells showed activity against cells resistant to ALK drugs. Patients take it by mouth in 21 day cycles.

This phase 1 trial plans 30 patients and studies safety and the best dose. At the University of Michigan in Ann Arbor, Angel Qin leads it.

Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT06225427

    Stage 4 ALK positive NSCLC progressed on other treatments, adults; Gilteritinib is already FDA approved for a specific type of leukemia; Studies with ALK positive lung cancer cells showed activity against resistant cells (stated as the registry's claim); By mouth, in 21 day cycles (+2 more lines)

The drug

What is being tested.

Gilteritinib is a drug that is already FDA approved for the treatment of a specific type of leukemia. However, studies using ALK positive lung cancer cells demonstrate activity of gilteritinib against these resistant cells.

The study

How the trial runs.

This phase I trial is studying the safety, side effects, and best dose of gilteritinib in treating patients with stage IV ALK positive non-small cell lung cancer (NSCLC) who have progressed on other treatments. While there are many approved targeted drugs for ALK NSCLC, resistance to these drugs frequently occur.

Therefore, in this clinical trial, the investigators plan to study the effect of gilteritinib in patients with ALK NSCLC.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Stage IV (American Joint Committee on Cancer [AJCC] 8th edition) non-small cell lung cancer with an oncogenic ALK fusion
  • Histologies include adenocarcinoma, squamous cell carcinoma, adenosquamous adenocarcinoma, and NSCLC NOS (not otherwise specified)
  • The presence of an oncogenic ALK fusion established from any Clinical Laboratory Improvement Act (CLIA) certified laboratory
  • Cohort 1: Prior 1st generation ALK tyrosine kinase inhibitor (TKI) (crizotinib) and/or prior 2nd generation TKI (ceritinib, brigatinib, alectinib) and/or lorlatinib
  • Cohort 2: Prior 1st generation ALK TKI (crizotinib) and/or prior 2nd generation TKI (ceritinib, brigatinib, alectinib) and/or lorlatinib, and platinum-doublet chemotherapy

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.